These conditions are far more common than we think, but we do not know how to detect them properly.
For patients whose tremors and faltering steps have long been misread as Parkinson's disease, a quieter and crueler diagnosis has often gone unnamed for years. Researchers at the Sant Pau Research Institute in Barcelona have demonstrated that advanced MRI imaging can distinguish progressive supranuclear palsy and corticobasal degeneration from one another and from Parkinson's with meaningful accuracy, even in the earliest stages of illness. These rare tauopathies — neurodegenerative conditions sharing a molecular kinship with Alzheimer's disease — have remained hidden in plain sight, their sufferers denied both correct diagnoses and access to trials that might one day offer relief. The finding suggests that the long silence around these conditions may, at last, be ending.
- PSP and CBD have spent decades misidentified as Parkinson's disease, leaving patients without correct diagnoses, appropriate care, or access to clinical trials designed for their actual condition.
- The biological confusion runs deep: because tau-driven neurodegeneration mimics Parkinson's motor symptoms so closely, drug trials enrolling patients by symptoms alone become scientifically muddied, obscuring whether treatments work at all.
- Sant Pau researchers identified distinct MRI atrophy signatures — brainstem-centered in PSP, cortex-heavy in CBD — that can reliably separate these diseases even when clinical symptoms still overlap.
- Using these imaging signatures as trial outcome measures could cut required patient numbers by 50% for PSP and up to 85% for CBD, transforming previously impractical trials into feasible ones.
- Backed by new Catalan health funding, the team is now combining plasma biomarkers with advanced imaging, aiming to replicate the early-detection model that has reshaped Alzheimer's disease research.
For years, clinicians have faced a diagnostic trap: a patient arrives with balance problems, stiffness, and slurred speech, and the most familiar answer — Parkinson's disease — is often wrong. Progressive supranuclear palsy and corticobasal degeneration produce nearly identical early symptoms, yet they are distinct neurodegenerative conditions caused by toxic tau protein accumulation, placing them closer to Alzheimer's disease than to Parkinson's in their underlying biology. The result has been chronic misdiagnosis, with patients spending years in the wrong diagnostic category and, critically, excluded from clinical trials targeting their actual disease.
Researchers at the Sant Pau Research Institute in Barcelona have now shown that advanced structural MRI can cut through this confusion. By identifying disease-specific patterns of brain atrophy — deep brainstem changes in PSP, pronounced cortical involvement in CBD — the team could reliably distinguish between conditions even at early stages when symptoms remain vague. Lead author Dr. Jesús García-Castro described the clinical reality plainly: without a reliable way to confirm underlying pathology, trial populations become biologically mixed, and even effective drugs can disappear into the noise.
The implications for therapeutic development are immediate. Clinical trials for rare diseases are already costly and difficult to recruit for. The Sant Pau analysis found that using MRI signatures as objective outcome measures could reduce required sample sizes by roughly 50% for PSP and 80 to 85% for CBD — the difference between a trial that is practically impossible and one that is genuinely viable.
The research has drawn continued investment, with the team now combining blood-based plasma biomarkers with advanced imaging to pursue early diagnosis of four-repeat tauopathies. The ambition is a diagnostic model resembling what now exists for Alzheimer's disease: a blood test and a scan, together offering reliable answers before the disease has progressed beyond reach. For patients who currently have no disease-modifying treatments and no clear path to trials, that ambition carries real weight.
Doctors have long struggled to tell the difference between three diseases that look almost identical when a patient walks into the clinic. A person with balance problems, stiffness, and slurred speech could have Parkinson's disease. Or they could have progressive supranuclear palsy. Or corticobasal degeneration. For years, clinicians guessed wrong so often that two of these conditions—PSP and CBD—became known as the underdiagnosed diseases, hidden inside a crowd of similar presentations.
Now researchers at the Sant Pau Research Institute in Barcelona have shown that advanced MRI imaging can tell these diseases apart with real accuracy, even when symptoms are still vague and overlapping. The finding, published in The Journal of Prevention of Alzheimer's Disease, matters because it opens a path toward earlier diagnosis and, more immediately, toward clinical trials that might actually work. Both PSP and CBD are tauopathies—neurodegenerative conditions caused by the toxic buildup of tau protein in the brain. They share this feature with Alzheimer's disease, but they damage different brain regions and progress differently. The confusion arises because their early motor symptoms—the tremor, the gait problems, the speech difficulties—mimic Parkinson's so closely that patients often receive the wrong diagnosis and never get enrolled in trials designed to test treatments for their actual condition.
Dr. Jesús García-Castro, the study's lead author and a neurologist at Hospital de Sant Pau, explained the clinical trap plainly: many patients initially present as if they had Parkinson's disease or are simply older adults with mobility difficulties. This means they are greatly underdiagnosed, and for years clinicians have not known with enough certainty which disease each patient actually had. The problem compounds when researchers try to design drug trials. If you enroll patients based only on their symptoms—because you have no reliable way to confirm the underlying pathology—you end up with a biologically mixed population. Some patients might actually have Alzheimer's disease masquerading as CBD. Others might have PSP. The trial becomes a muddy experiment, and even if a drug works, the noise in the data obscures the signal.
The Sant Pau team identified disease-specific patterns of brain atrophy visible on structural MRI scans. In PSP, the signature involves deep brain structures, particularly the brainstem, along with selective changes in certain cortical areas. CBD shows a different pattern: more marked involvement of the cortex itself, especially regions controlling movement and sensory processing. By combining these regional changes into a signature, the researchers could estimate with high probability whether a patient had PSP or CBD, even at very early stages when symptoms were still nonspecific. Dr. Ignacio Illán-Gala, senior author of the study, noted that although the diseases look very similar clinically, at the brain level PSP and CBD damage tissue in different ways, and those differences show up on MRI.
The practical impact is substantial. Clinical trials for rare diseases are already hard to recruit for and expensive to run. Traditional trial designs rely on clinical scales—measures of symptom severity and function—to detect whether a treatment works. For PSP and CBD, this approach requires following hundreds of patients for long periods. The Sant Pau analysis showed that using MRI signatures as objective outcome measures could shrink those numbers dramatically. In PSP, a disease-specific MRI signature could reduce the required sample size by roughly 50 percent in a 12-month trial. In CBD, where clinical heterogeneity is even greater, the reduction could reach 80 to 85 percent. For a pharmaceutical company or academic consortium deciding whether to fund a trial, feasibility is everything. A trial requiring a thousand patients is practically impossible. A trial with a reasonable number of well-selected individuals and objective measures of progression suddenly becomes viable.
The research has already attracted continued funding. The Sant Pau team received support from the PERIS program of the Catalan Department of Health to advance early diagnosis of four-repeat tauopathies by combining plasma biomarkers—blood tests—with advanced imaging. The goal is to reach a situation similar to Alzheimer's disease, where a blood test and an MRI scan together allow reliable diagnosis at very early stages. García-Castro emphasized that these conditions are far more common than most people think, but clinicians do not yet know how to detect them properly. Improving diagnosis is the first step so that patients who currently have no therapeutic options can begin to have them.
Citações Notáveis
For years, clinicians have not known with enough certainty which disease each patient actually had, meaning they are greatly underdiagnosed.— Dr. Jesús García-Castro, lead author, Sant Pau Research Institute
If a trial requires a thousand patients, it is practically impossible. But if it can be conducted with a reasonable number of well-selected individuals and objective measures of progression, then there is a real chance of demonstrating whether a treatment works.— Dr. Ignacio Illán-Gala, senior author, Sant Pau Research Institute
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter so much that we can tell PSP from CBD on an MRI if there's no treatment for either one anyway?
Because right now, the lack of a reliable diagnosis is actually preventing treatments from being developed. If you can't accurately identify who has the disease, you can't run a clean trial. You end up with biologically mixed populations where the signal gets lost in the noise.
So the MRI doesn't cure anyone directly—it just makes it possible to test whether a cure might work?
Exactly. And it does something else too. It lets you enroll the right patients. A person who's been misdiagnosed for years finally knows what they actually have. That matters for their own care, even before any new drug exists.
The study mentions an 80 percent reduction in trial size for CBD. That seems almost too good to be true.
It's not magic. It's about signal-to-noise. When you measure disease progression with a clinical scale, there's a lot of variability—some days the patient feels better, some days worse. MRI shows actual structural brain changes. That's a cleaner, more objective measure. Fewer patients needed to see the effect.
What happens to the patients who are currently misdiagnosed? Do they get reclassified?
That's the hope. Once this becomes standard practice, yes. But right now, many people are still walking around thinking they have Parkinson's when they actually have PSP or CBD. The research team is working on making this accessible—combining blood tests with MRI so diagnosis becomes easier and faster.
And the blood test part—that's the next frontier?
It is. Blood biomarkers are cheaper and faster than MRI. If you can do a blood test first to narrow down the possibilities, then use MRI to confirm, you've got a practical diagnostic pathway. That's what they're building toward now.